Loading...
Loading...
XENE| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.7M |
| Gross Profit | -0.7M |
| Operating Expense | 68.4M |
| Operating I/L | -69.1M |
| Other Income/Expense | 10.8M |
| Interest Income | 10.8M |
| Pretax | -58.3M |
| Income Tax Expense | -0.3M |
| Net Income/Loss | -57.9M |
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Canada. The company focuses on developing therapeutics for neurological disorders. Its product pipeline includes XEN496, a Kv7 potassium channel opener in Phase III clinical trials for KCNQ2 developmental and epilepsy encephalopathy; XEN1101, a Kv7 potassium channel opener in Phase II clinical trial for epilepsy and other neurological disorders; NBI-921352, a selective Nav1.6 sodium channel inhibitor in Phase II clinical trials for SCN8A developmental and epileptic encephalopathy; and XEN007, a central nervous system-acting calcium channel modulator in Phase II clinical trials. Xenon also has collaboration agreements with Neurocrine Biosciences, Inc. and Flexion Therapeutics, Inc. for the development of treatments for epilepsy and post-operative pain, respectively.
